ESOPHAGEAL ADENOCARCINOMA

This early-phase trial tests a new treatment for people with a type of stomach cancer that has spread to the lining of the abdomen. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to chec…

This early-phase study tests whether a new drug called NRM-823 is safe and tolerable for people with advanced solid tumors that have not responded to other treatments. About 150 participants with cancers like lung, ovarian, or triple-negative breast cancer will receive NRM-823 al…

This early-stage trial tests a drug called sigvotatug vedotin, alone or with other medicines, in people with advanced solid tumors like lung, head and neck, or breast cancer. The goal is to find a safe dose and check for side effects. About 1,000 participants will join this study…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for patients with resectable stomach, esophageal, or gastroesophageal junction cancer. The goal is to see if this approach is safe and effe…

This study is the first time the experimental drug KK2269 is being tested in people. It aims to check the safety of KK2269 given alone or with the chemotherapy drug docetaxel. The trial involves about 101 adults with advanced solid tumors (like stomach, lung, or esophageal cancer…

This study tests a combination of two or three drugs (cabozantinib, durvalumab, and possibly tremelimumab) in people with advanced stomach, esophageal, liver, or colorectal cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the treatment can …

This early-stage study tests a new drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 330 partici…

This study tests a new drug called denikitug, either alone or with other treatments, for people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has spread or come back. About 120 participants will be randomly assigned to different treatme…

This study tests whether a new drug, OBP-301, injected directly into tumors, can make the immunotherapy drug pembrolizumab work better for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is PD-L1-negative or has stopped responding to immunothera…

This study tests whether adding a second round of targeted treatment (called cytoreductive intervention) after standard chemotherapy can help people with advanced upper GI cancers live longer without the disease getting worse. It is for patients whose cancer has spread but whose …

This study tests a new medicine (PF-08634404) combined with chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new combo t…

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, esophageal, or pancreatic cancers that have spread. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to check safety and see if the drug can shrink tu…

This study tests an experimental oral drug called zongertinib, which blocks HER2 (a protein that fuels cancer growth). It is given alone or with other standard treatments to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and no longer responds to…

This study tests a new mix of chemotherapy drugs and immunotherapy for people with advanced esophageal or stomach cancer. The goal is to see if this combination works better and causes fewer side effects than current treatments. About 52 adults with these cancers will take part.

This early-stage study tests a new treatment called DISP-10, which combines a virus and specially engineered immune cells, for people with advanced stomach, esophageal, or colorectal cancers that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 66 …

This study tests whether adding itraconazole, a widely used antifungal medication, to standard chemotherapy and radiation can improve outcomes for people with esophageal cancer. About 78 participants with resectable tumors will receive itraconazole before surgery. The goal is to …

This study tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy helps people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 and PD-L1) w…

This early-stage study tests a new drug called BL-M05D1 in about 160 adults with advanced or metastatic solid tumors, including stomach, pancreatic, esophageal, and bile duct cancers. The main goals are to find safe doses and understand side effects. Participants must have tried …

This study tests a new drug called PLX-61639 in adults with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken daily by mouth and aims to shrink or control the cancer. The trial will e…

This study tests whether adding the blood pressure drug propranolol to standard chemoradiation is safe and effective for people with esophageal adenocarcinoma. About 106 participants will receive the combination, and researchers will monitor side effects and how long the cancer s…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests a new drug combination (telisotuzumab adizutecan, budigalimab, and two standard chemotherapies) as a first treatment for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 participants will r…

This early-phase trial tests adding a precise, MRI-guided radiation treatment after standard chemotherapy for people with esophageal adenocarcinoma. The goal is to find the highest safe radiation dose that can improve tumor control without causing severe side effects like fistula…

This study tests a new, less invasive way to screen for Barrett's esophagus, a condition that can lead to esophageal cancer. Instead of using a long tube with a camera (endoscopy), participants swallow a small sponge on a string that collects cells from the esophagus. The collect…

This study tests a simple sponge-on-a-string device that people swallow to collect cells from the esophagus. The goal is to see if this non-invasive test can accurately detect Barrett's esophagus and early signs of esophageal cancer in people aged 50-85 with risk factors like chr…

This study tests a new imaging method called quantitative fluorescence molecular endoscopy (qFME) to find early cancerous changes in the esophagus of people with Barrett's esophagus. Participants will receive two fluorescent dyes (bevacizumab-800CW and cetuximab-800CW) either by …

This study aims to see if a new office-based test can detect Barrett's esophagus—a condition that can lead to esophageal cancer—in people who do not have chronic heartburn. About 800 adults will answer a questionnaire, swallow a capsule balloon to collect cells, and have a lab te…

This study tests whether obeticholic acid can prevent cancer in people with Barrett's esophagus, a condition that raises the risk of esophageal cancer. The drug works by reducing damage from bile acids that flow back into the esophagus. About 30 adults with Barrett's esophagus wi…

This study aims to improve how doctors monitor Barrett's esophagus, a condition that can lead to esophageal cancer. Researchers will collect tissue samples using a brush during routine endoscopy and analyze them with advanced genetic tests. The goal is to develop a risk model tha…

This study is a registry that collects information on how patients with advanced esophageal, stomach, or gastroesophageal junction cancer are treated in everyday medical practice in Germany. It will include about 1,900 adults who are starting their first palliative therapy. The g…

This study looks for Barrett's esophagus, a condition that can lead to cancer, in 25 adults with eating disorders who have been purging (vomiting or ruminating) for at least 5 years. Researchers will use a simple, non-endoscopic test to see how common Barrett's is in this group. …

This study looks at two common ways to manage Barrett's esophagus with low-grade dysplasia—a condition where the lining of the esophagus has abnormal cells that rarely turn into cancer. One approach is regular check-ups with a camera and small tissue samples (surveillance). The o…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…